The INTerpath-001 trial randomized 1,137 patients with resected stage IIB to IV melanoma to Keytruda alone or Keytruda plus ...
TMT, has shown a strong tumor progression benefit in first-line, PD-L1-negative non-small cell lung cancer in a China phase 3 ...
Merck & Co. and Moderna always knew they would be making headlines in Madrid this week—just not in the way it panned out. | Merck & Co. and Moderna always knew they would be making headlines in Madrid ...
Merck is strengthening its semiconductor manufacturing footprint in South Korea with a new molybdenum production facility designed to accelerate next-generation chip development, secure local supplies ...
Investor's Business Daily on MSN
How Halozyme, up nearly 90% this year, is rivaling Merck and hitting new highs
Halozyme makes technologies that allow drugs delivered through intravenous infusion, or IV, to instead be given with ...
Merck's Courtney Ronaldo discusses the strategy behind the company's new oncology campaign, its multichannel presence at ESMO ...
1d
Doctors call Moderna, Merck cancer vaccine data a major advancement — despite Wall Street reaction
Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma ...
Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding ...
Moderna and Merck's personalized mRNA vaccine, combined with Keytruda, reduces melanoma recurrence or death risk in Phase 3 ...
Pfizer's 5.7% dividend yield towers over Merck's, yet that gap may signal something retirees cannot afford to ignore. Before ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results